Articles by Katy Marshall
A lack of research persists on the duration of therapy as well as the safety and efficacy of reinduction at progression.
177Lu-PSMA-617 is a PSMA-targeted radioligand therapy in patients with mCRPC.
The hypoxia-inducible factor 2α inhibitor, belzutifan, has shown clinical activity in patients with ccRCC.
A previous study found 64Cu-SAR-bisPSMA to be safe and effective in identifying prostate cancer lesions in patients with BCR.
The study presented the results of cohorts 4 and 5 from the phase 2 KEYNOTE-199 study.
A meta-analysis sought to determine the surgical and oncological outcomes of LNU and ONU in patients with UTUC.
Black patients are often under-represented in oncology clinical trials.
Patients either underwent 54 weeks of treatment with everolimus 10 mg per day or treatment with a matching placebo.
In patients with MIBC, any tumors with ATM, RB1, FANCC, or ERCC2 mutations were likely to respond to treatment with NAC.
There is a lack of research investigating associations between bone pain and OS in patients with mHSPC.
Patients who received nivolumab plus ipilimumab experienced increased complete response rates compared with sunitinib.
Researchers stated that the novel data source has the potential to inform patient care.
The study’s data set included abstracted clinical data with germline and tumor genomic data.
Data show that of patients with prostate cancer, Black men face higher incidence and mortality rates than White men.
Researchers focused on the economic impact of disparities related to insurance coverage.
Researchers evaluated the data of 50 specimens from patients who underwent TURBT and cystectomy for UC.
The primary end point was ORR according to Immune Response Evaluation Criteria in Solid Tumors at 4 months.
Researchers evaluated the tissue samples of 126 treatment-naïve patients collected from a multicenter database.
Patients were sorted into groups based on modifiable lifestyle behaviors and genetic risk.
The new recommendations included changes to neoadjuvant and adjuvant chemotherapy and radical cystectomy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.